The genetic basis of sleep is still poorly understood. Despite the moderate to high heritability of sleep-related phenotypes, known genetic variants explain only a small proportion of the phenotypical variance. However, most previous studies were based solely upon self-report measures. The present study aimed to conduct the first genome-wide association (GWA) of actigraphic sleep phenotypes. The analyses included 956 middle- to older-aged subjects (40-79 years) from the LIFE Adult Study. The SenseWear Pro 3 Armband was used to collect 11 actigraphic parameters of night- and daytime sleep and three parameters of rest (lying down). The parameters comprised measures of sleep timing, quantity and quality. A total of 7 141 204 single nucleotide polymorphisms (SNPs) were analysed after imputation and quality control. We identified several variants below the significance threshold of P ≤ 5× 10 (not corrected for analysis of multiple traits). The most significant was a hit near UFL1 associated with sleep efficiency on weekdays (P = 1.39 × 10 ). Further SNPs were close to significance, including an association between sleep latency and a variant in CSNK2A1 (P = 8.20 × 10 ), a gene known to be involved in the regulation of circadian rhythm. In summary, our GWAS identified novel candidate genes with biological plausibility being promising candidates for replication and further follow-up studies.
Background: Different levels of brain arousal can be delineated not only during sleep but also during wakefulness. Electroencephalography (EEG) is the gold standard to assess different levels of brain arousal. A novel EEG-and electrooculography (EOG)-based tool, the Vigilance Algorithm Leipzig (VIGALL 2.0), allows determining the level of EEG-vigilance (indicating brain arousal). Considering the frequency patterns and LORETA-based cortical distribution of electroencephalic activity, VIGALL 2.0 automatically attributes one out of seven vigilance stages to each EEG segment (1-sec EEG segments by default), ranging from high alertness (stage 0), to relaxed wakefulness (stage A1 to A3), to drowsiness (stage B1 to B2/3) up to sleep onset (stage C). Building on the time series of these seven vigilance stages across 20 min, two parameterizations of the temporal dynamic (brain arousal regulation) are calculated: the lability score and the slope index. Methods: 27 healthy participants (age = 22.93 ± 3.44 years, 18 females) underwent two sessions (7 days apart) of a twenty-minute eyes-closed resting EEG paradigm. Results:The test-retest reliability coefficients for the EEG-vigilance stages were between rho = .53 and .86 (all p < .01). For the temporal dynamic of the stages across 20 min, the test-retest reliability coefficients were rho = .70 (lability score, p < .001) and .71 (slope index, p < .001).Conclusions: This study demonstrated some trait aspects of brain arousal regulation by confirming the stability of temporal dynamic of EEG-vigilance stages as assessed with VIGALL 2.0. Considering the "first day in lab" effect identified in the present study, more adaptation to the lab surrounding and a stricter control of other state factors should be taken into account, which might improve reliability. Additionally, in a clinical context, a broader range of brain arousal regulation patterns might be found, possibly leading to higher test-retest reliability than was found in this homogenous healthy sample. This would be desirable, as parameters of brain arousal regulation are promising diagnostic and prognostic biomarkers for diseases with arousal disturbances, such as affective disorders, ADHD and fatigue.
BackgroundPrevious studies compared evoked potentials (EPs) between several sleep stages but only one uniform wake state. However, using electroencephalography (EEG), several arousal states can be distinguished before sleep onset. Recently, the Vigilance Algorithm Leipzig (VIGALL 2.0) has been developed, which automatically attributes one out of seven EEG-vigilance stages to each 1-s EEG segment, ranging from stage 0 (associated with cognitively active wakefulness), to stages A1, A2 and A3 (associated with relaxed wakefulness), to stages B1 and B2/3 (associated with drowsiness) up to stage C (indicating sleep onset). Applying VIGALL, we specified the effects of these finely differentiated EEG-vigilance stages (indicating arousal states) on EPs (P1, N1, P2, N300, MMN and P3) and behavioral performance. Subjects underwent an ignored and attended condition of a 2-h eyes-closed oddball-task. Final analysis included 43 subjects in the ignored and 51 subjects in the attended condition. First, the effect of brain arousal states on EPs and performance parameters were analyzed between EEG-vigilance stages A (i.e. A1, A2 and A3 combined), B1 and B2/3&C (i.e. B2/3 and C combined). Then, in a second step, the effects of the finely differentiated EEG-vigilance stages were further specified.ResultsComparing stages A versus B1 versus B2/3&C, a significant effect of EEG-vigilance stages on all behavioral parameters and all EPs, with exception of MMN and P3, was found. By applying VIGALL, a more detailed view of arousal effects on EP and performance was possible, such as the finding that the P2 showed no further significant increase in stages deeper than B1. Stage 0 did not differ from any of the A-stages. Within more fine-graded stages, such as the A-substages, EPs and performance only partially differed. However, these analyses were partly based on small sample sizes and future studies should take effort to get enough epochs of rare stages (such as A3 and C).ConclusionsA clear impact of arousal on EPs and behavioral performance was obtained, which emphasize the necessity to consider arousal effects when interpreting EPs.Electronic supplementary materialThe online version of this article (doi:10.1186/s12868-017-0340-9) contains supplementary material, which is available to authorized users.
No abstract
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.